Year : 2019 | Volume
: 9 | Issue : 4 | Page : 216--223
Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?
Lihteh Wu1, Dhariana Acón2, Andrés Wu4, Max Wu3
1 Macula, Vitreous and Retina Associates of Costa Rica, San José, Costa Rica; Illinois Eye and Ear Infirmary, University of Illinois, Chicago, Illinois, USA
2 Department of Ophthalmology, Bascom Palmer Eye Insitute, Miami, FL, USA
3 Macula, Vitreous and Retina Associates of Costa Rica, San José, Costa Rica; College of Engineering, Cornell University, Ithaca, NY, USA
Prior to the development of panretinal photocoagulation (PRP) in the 1970s, proliferative diabetic retinopathy (PDR) was the most common cause of blindness in diabetic patients. The diabetic retinopathy study demonstrated that PRP could decrease severe visual loss from PDR by 50%. Since then and for the past four decades, PRP has been the treatment of choice for eyes with PDR. In the past decade, vascular endothelial growth factor (VEGF) inhibition has become the treatment of choice for diabetic macular edema (DME). When treated intensively with anti-VEGF drugs, about one-third of eyes with DME experience an improvement in their diabetic retinopathy severity scale. Randomized clinical trials comparing ranibizumab to PRP and aflibercept to PRP have shown that VEGF inhibitors cause regression of intraocular neovascularization but need to be given on a fairly regular basis. Despite these promising results, concerns about treatment adherence have surfaced. Patients with PDR that are treated solely with anti-VEGF drugs and somehow interrupt their treatment are at a high risk of developing irreversible blindness. Combination treatment of PRP plus an anti-VEGF drug may be the treatment of choice for PDR.
Dr. Lihteh Wu
Macula, Vitreous, Retina Associates of Costa Rica, First Floor, Mercedes Tower, Paseo Colon, San Jose
|How to cite this article:|
Wu L, Acón D, Wu A, Wu M. Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?.Taiwan J Ophthalmol 2019;9:216-223
|How to cite this URL:|
Wu L, Acón D, Wu A, Wu M. Vascular endothelial growth factor inhibition and proliferative diabetic retinopathy, a changing treatment paradigm?. Taiwan J Ophthalmol [serial online] 2019 [cited 2020 Feb 26 ];9:216-223
Available from: http://www.e-tjo.org/article.asp?issn=2211-5056;year=2019;volume=9;issue=4;spage=216;epage=223;aulast=Wu;type=0